Skip to content

Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors

Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06266949
Enrollment
30
Registered
2024-02-20
Start date
2026-12-01
Completion date
2027-12-01
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Tumor, Visual Fields Hemianopsia

Brief summary

The purpose of this study is to assess wether the SONDA visual field test is suitable for patients with a supra sellar tumour.

Detailed description

The objective of this study is to determine whether SONDA is non-inferior in predicting visual field limitations compared to the SAP in patients with a (supra)sellar tumor. The study population will be made up of patients with a (supra)sellar tumor complicated by compression of the optic chiasm as well as healthy controls. The patients will be asked to join the study when the patients are referred to the UMCG for further diagnostics and treatment. In case the patients show signs of visual field loss the patients will be asked to participate in the study. The researchers will reuse data from healthy controls collected in previous studies where possible and, if necessary for age matching, recruit new participants. Participants will be asked to perform the SONDA test before and after surgery. The first time the participants will perform the test twice and will also perform routine eye test and be asked to fill in a questionnaire to evaluate the experience.

Interventions

DIAGNOSTIC_TESTSONDA

Perimetry based visualfield analysis

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Diagnosed with a (supra)sellar tumor * Visual field loss based on the most recent SAP; False positive rate \<15%; fixation losses \<20% * Informed written consent

Exclusion criteria

* Neurological disorders * Eye disease not related to a (supra)sellar tumor

Design outcomes

Primary

MeasureTime frameDescription
Convert validityBaselineDifference (dB) between the predicted MD (SONDA) and the assessed MD (SAP), expressed as delta MD.
Test-retest reliabilitybaseline 1, baseline 2, 6-8 weeks post-operativeThe variability of the predicted MD (dB) between consecutive measurements in the same person.

Secondary

MeasureTime frameDescription
ExperienceBaselineThe experience of patients expressed in scores and descriptives based on a questionnaire: Questionnaire Standardized Oculomotor and Neuro-Ophthalmic Disorder Assessment

Countries

Netherlands

Contacts

CONTACTJos MA Kuijlen, MD/PHD
jmakuijlen@umcg.nl050 361 2837
PRINCIPAL_INVESTIGATORJos MA Kuijlen, MD/PHD

University Medical Center Groningen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026